A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.